CONSTANCE ANTON: Open Payments
NPI 1679656904 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$613 in 28 payments from 13 companies in 2025. Trend: 2023 $128 · 2024 $305 · 2025 $613
Food & beverage: $613
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $145 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Janssen Pharmaceuticals, Inc | 3 | $65 |
| Lundbeck LLC | 3 | $50 |
| ABBVIE INC. | 2 | $48 |
| E.R. Squibb & Sons, L.L.C. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
Products named: UZEDY, REXULTI, VRAYLAR, ABILIFY MAINTENA, COBENFY, AUSTEDO XR, TRINTELLIX, INVEGA SUSTENNA.
Industry payments across MD — which companies pay providers there.
